Targeting monocytic‐myeloid suppressor cells through CSF1R‐blockade enhances CD19‐CAR T‐cell response in DLBCL.

To investigate CAR T cell therapy in an immunocompetent autochthonous mouse model we established murine CD19-redirected CAR-T cells that were generated using splenic T cells isolated from mice harbouring a C57BL/6N background. Targeting monocytic-myeloid suppressor cells through CSF1R-blockade enhances CD19-CAR T-cell response in DLBCL B Introduction: b Adoptive immunotherapies such as chimeric antigen receptor (CAR) T cell therapy have strongly improved the outcome of patients with diffuse large cell lymphoma (DLBCL) that are relapsed or refractory after standard chemo-immunotherapy. [Extracted from the article]